Le Lézard
Classified in: Health, Science and technology, Business
Subject: VEN

Duality Health Begins Rapid Blockchain Innovation Cycle with Health Product Innovation Team at Dell Medical School


AUSTIN, Texas, Aug. 5, 2020 /PRNewswire/ -- Duality Health, a digital health company specializing in identity management, today announced the company's membership in the philanthropic Founders Circle of Dell Medical School at The University of Texas at Austin as well as a collaboration that brings together technology, academia, and industry stakeholders to focus on blockchain and healthcare innovation. 

This collaboration between Dell Med's Health Product Innovation team and Duality Health is a first step in establishing a sustainable Blockchain Innovation Hub that will ultimately enable rapid and efficient problem identification and solution iterations with the goal of clinical and commercially viable Blockchain-based products in healthcare.

The first innovation cycle is already underway to identify critical needs and develop prototype solutions leveraging Duality's robust blockchain infrastructure, Dynamic. The Dynamic blockchain functions as a highly redundant and available API framework for which to build and host interoperable health applications.

"Dell Med provides a world-class research environment to further validate a blockchain-based approach to solving some of healthcare's biggest challenges," said Clayton Saliba, CEO and Co-Founder of Duality. "Our passion aligns with the school's efforts to 'rethink everything', explore new possibilities, and develop novel technologies that will ultimately improve health care for all." 

On the back of this announcement comes the news that Duality has secured cornerstone investors Bandera Capital and Sapien Ventures in the company's ongoing pre-Seed round of investment. 

"We believe blockchain technology will be a keystone in the future of healthcare and are excited to support forward-thinking organizations like Duality and Dell Med," said Gabriel Reyna, Managing Partner at Bandera Capital. 

About Duality Health 

Duality Health is a fast-growing startup focused on the nexus between healthcare data and blockchain technology. Founded in 2018, Duality's mission is to develop a highly secure and interoperable blockchain ecosystem to accurately identify, manage, track, and link global health data. The company's product suite includes Patient Identity Management, Practitioner Single-Sign-On, and Electronic Health Data Exchange. Duality's founders and employees are dedicated to making health care safer and more affordable to all.

Media Contact:
Allie Perez
726-999-0067
[email protected]

Related Links
https://duality.health
https://duality.solutions

SOURCE Duality Health Inc.


These press releases may also interest you

at 17:00
StateHouse Holdings Inc. ("StateHouse" or the "Company") , a California-focused, vertically integrated cannabis company, today announced further to its press release dated April 15, 2024, that the Ontario Securities Commission (the "OSC") has denied...

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...



News published on and distributed by: